王祎,王军,程云杰,刘青,张萍,吴凤鹏,万欣,张钧.血清细胞因子TGF-β1和IL-1β表达水平对急性放射性心脏损伤发生的影响[J].中华放射医学与防护杂志,2012,32(5):488-491
血清细胞因子TGF-β1和IL-1β表达水平对急性放射性心脏损伤发生的影响
Effect of TGF-β1 and IL-1β expression in serum on acute radiation-induced heart disease
投稿时间:2012-02-16  
DOI:10.3760/cma.j.issn.0254-5098.2012.05.009
中文关键词:  三维适形放射治疗  调强放射治疗  放射性心脏损伤  转化生长因子-β1  白介素-1β
英文关键词:Three-dimensiond conformal radiotherapy  Intensity modulated radiotherapy  Radiation induced heart disease  Transforming growth factor-β1  Human interleukin-1β
基金项目:河北省二〇〇九年医学科学研究重点课题(20090502)
作者单位E-mail
王祎 050011 石家庄, 河北医科大学第四医院放疗一科  
王军 050011 石家庄, 河北医科大学第四医院放疗一科 wangjun90@yahoo.com.cn 
程云杰 050011 石家庄, 河北医科大学第四医院放疗一科  
刘青 050011 石家庄, 河北医科大学第四医院放疗一科  
张萍 050011 石家庄, 河北医科大学第四医院放疗一科  
吴凤鹏 050011 石家庄, 河北医科大学第四医院放疗一科  
万欣 050011 石家庄, 河北医科大学第四医院放疗一科  
张钧 050011 石家庄, 河北医科大学第四医院放疗一科  
摘要点击次数: 3370
全文下载次数: 2451
中文摘要:
      目的 研究胸部肿瘤放射治疗患者血清TGF-β1和IL-1β水平对急性放射性心脏损伤发生的影响。方法 接受常规适形或调强放疗的胸部肿瘤患者54例,PTV处方剂量为50~66 Gy,分析靶区剂量分布及危及器官受量。患者于放疗前及放疗结束后空腹采肘静脉血,应用酶联免疫吸附法检测血清中TGF-β1和IL-1β水平,并分别在放疗前后和放疗开始90 d内检测心肌酶、肌钙蛋白Ⅰ、心电图以及心功能指标评价患者心脏损伤状况,对急性放射性心脏损伤分级标准进行评价。分析血清TGF-β1和IL-1β水平对急性放射性心脏损伤的影响。结果 放疗前患者血清TGF-β1为(888.4±41.1)μg/L,放疗结束时为(926.1±23.1)μg/L,差异有统计学意义(t=-6.479, P<0.05);放疗后发生急性放射性心脏损伤患者血清TGF-β1为(900.6±34.5)μg/L,高于无急性放射性心脏损伤患者的(865.7±47.0) μg/L,差异有统计学意义(t=-2.646,P<0.05)。Spearman相关分析显示,TGF-β1放疗前基础水平、放疗前后差值与急性放射性心脏损伤相关(r=0.378、0.311,P<0.05)。患者放疗前与放疗结束时的血清IL-1β比较差异无统计学意义;放疗后发生急性放射性心脏损伤者与未发生急性放射性心脏损伤者血清IL-1β基础表达水平差异无统计学意义。患者放疗前IL-1β基础水平、放疗后表达水平、放疗前后差值与急性放射性心脏损伤无相关性。放疗前、后TGF-β1的表达水平与放疗后IL-1β的表达水平呈正相关(r=0.416、0.389,P<0.05)。结论 放疗后血清TGF-β1升高,放疗前基础表达水平及放疗前后差值与急性放射性心脏损伤相关。IL-1β与放射性心脏损伤无相关性。
英文摘要:
      Objective To evaluate the effect of TGF-β1 and IL-1β expression in serum on acute radiation-induced heart disease (RIHD) in patients with thoracic tumors.Methods Three-dimensional conformal radiotherapy (3D-CRT) or intensity modulated radiotherapy (IMRT) was delivered at 1.8-2.0Gy, 5 times per week to a total dose of 50-66Gy to 44 patients with lung cancer and 10 patients with esophagus cancer. The target and organs at risk dose distribution were analyzed by 3-dimensiond treatment planning system. The expressions of TGF-β1 and IL-1β in serum were detected by enzyme linked immunosorbent assay before and at the end of the irradiation. The cardiac injury was evaluated by detecting the cmyocardium creatase,cardiac troponin I (cTnI), electrocardiogram and cardiac function before and at the end of the irradiation within 90 d. The acute RIHD was evaluated by the Common Terminology Criteria V 3.0 (NCI-CTCAE 3.0). The expressions of TGF-β1 and IL-1β in the serum of RIHD patients with thoracic tumors were analyzed. Results The expression of TGF-β1 in serum was (888.4±41.1) μg/L before the irradiation and approached to (926.1±23.1) μg/L at the end of the radiotherapy.The expression level of TGF-β1 in the serum of acute RIDH group was (900.6±34.5) μg/L, higher than that of normal group [(865.7±47.0) μg/L, t=-2.646, P<0.05)]. The acute RIDH was correlated with the expression level of TGF-β1 before irradiation and the difference before and at the end of irradiation (r=0.378,0.311, P<0.05). The IL-1β expression had no significant difference before and after irradiation. The expression of TGF-β1 in serum before and at the end of irradiation had positive correlation with the expression of IL-1β at the end of the irradiation (r=0.416,0.389, P<0.05). Conclusions The expression of TGF-β1 in the serum of patients with thoracic tumor increases after irradiation and correlated with the acute RIHD, but the expression of IL-1β in serum has no relationship with RIHD. TGF-β1 could induce the expression of IL-1β at the end of the irradiation.
HTML  查看全文  查看/发表评论  下载PDF阅读器
关闭